Search

Your search keyword '"Wirachwong, Ponthip"' showing total 14 results
Start Over Author "Wirachwong, Ponthip"
14 results on '"Wirachwong, Ponthip"'

1. Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18–64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial

Author

Prasert, Kriengkrai, Praphasiri, Prabda, Lerdsamran, Hatairat, Nakphook, Sutthichai, Ditsungnoen, Darunee, Chawalchitiporn, Sutthinan, Sornwong, Kanlaya, Poopipatpol, Kittisak, Wirachwong, Ponthip, Narakorn, Piengthong, Surichan, Somchaiya, Suthepakul, Nava, Thangsupanimitchai, Napawan, Pittayawonganon, Chakrarat, Puthavathana, Pilaipan, Davis, William W., Mott, Joshua A., Olsen, Sonja J., and Patumanond, Jayanton

Published
2024
Full Text
View/download PDF

2. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

Author

Pitisuttithum, Punnee, Luvira, Viravarn, Lawpoolsri, Saranath, Muangnoicharoen, Sant, Kamolratanakul, Supitcha, Sivakorn, Chaisith, Narakorn, Piengthong, Surichan, Somchaiya, Prangpratanporn, Sumalee, Puksuriwong, Suttida, Lamola, Steven, Mercer, Laina D., Raghunandan, Rama, Sun, Weina, Liu, Yonghong, Carreño, Juan Manuel, Scharf, Rami, Phumratanaprapin, Weerapong, Amanat, Fatima, Gagnon, Luc, Hsieh, Ching-Lin, Kaweepornpoj, Ruangchai, Khan, Sarwat, Lal, Manjari, McCroskery, Stephen, McLellan, Jason, Mena, Ignacio, Meseck, Marcia, Phonrat, Benjaluck, Sabmee, Yupa, Singchareon, Ratsamikorn, Slamanig, Stefan, Suthepakul, Nava, Tcheou, Johnstone, Thantamnu, Narumon, Theerasurakarn, Sompone, Tran, Steven, Vilasmongkolchai, Thanakrit, White, Jessica A, Bhardwaj, Nina, Garcia-Sastre, Adolfo, Palese, Peter, Krammer, Florian, Poopipatpol, Kittisak, Wirachwong, Ponthip, Hjorth, Richard, and Innis, Bruce L

Published
2022
Full Text
View/download PDF

3. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

Author

Sun, Weina, Liu, Yonghong, Amanat, Fatima, González-Domínguez, Irene, McCroskery, Stephen, Slamanig, Stefan, Coughlan, Lynda, Rosado, Victoria, Lemus, Nicholas, Jangra, Sonia, Rathnasinghe, Raveen, Schotsaert, Michael, Martinez, Jose L., Sano, Kaori, Mena, Ignacio, Innis, Bruce L., Wirachwong, Ponthip, Thai, Duong Huu, Oliveira, Ricardo Das Neves, Scharf, Rami, Hjorth, Richard, Raghunandan, Rama, Krammer, Florian, García-Sastre, Adolfo, and Palese, Peter

Published
2021
Full Text
View/download PDF

4. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial

Author

Pitisuttithum, Punnee, Boonnak, Kobporn, Chamnanchanunt, Supat, Puthavathana, Pilaipan, Luvira, Viravarn, Lerdsamran, Hatairat, Kaewkungwal, Jaranit, Lawpoolsri, Saranath, Thanachartwet, Vipa, Silachamroon, Udomsak, Masamae, Wanibtisam, Schuetz, Alexandra, Wirachwong, Ponthip, Thirapakpoomanunt, Sit, Rudenko, Larisa, Sparrow, Erin, Friede, Martin, and Kieny, Marie-Paule

Published
2017
Full Text
View/download PDF

5. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination

Author

Carreño, Juan Manuel, primary, Raskin, Ariel, additional, Singh, Gagandeep, additional, Tcheou, Johnstone, additional, Kawabata, Hisaaki, additional, Gleason, Charles, additional, Srivastava, Komal, additional, Vigdorovich, Vladimir, additional, Dambrauskas, Nicholas, additional, Gupta, Sneh Lata, additional, González Domínguez, Irene, additional, Martinez, Jose Luis, additional, Slamanig, Stefan, additional, Sather, D. Noah, additional, Raghunandan, Rama, additional, Wirachwong, Ponthip, additional, Muangnoicharoen, Sant, additional, Pitisuttithum, Punnee, additional, Wrammert, Jens, additional, Suthar, Mehul S., additional, Sun, Weina, additional, Palese, Peter, additional, García-Sastre, Adolfo, additional, Simon, Viviana, additional, and Krammer, Florian, additional

Published
2023
Full Text
View/download PDF

6. The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines

Author

Carreño, Juan Manuel, primary, Raskin, Ariel, additional, Singh, Gagandeep, additional, Tcheou, Johnstone, additional, Kawabata, Hisaaki, additional, Gleason, Charles, additional, Srivastava, Komal, additional, Vigdorovich, Vladimir, additional, Dambrauskas, Nicholas, additional, Gupta, Sneh Lata, additional, Gonzalez, Irene, additional, Martinez, Jose Luis, additional, Slamanig, Stefan, additional, Sather, D. Noah, additional, Raghunandan, Rama, additional, Wirachwong, Ponthip, additional, Muangnoicharoen, Sant, additional, Pitisuttithum, Punnee, additional, Wrammert, Jens, additional, Suthar, Mehul S., additional, Sun, Weina, additional, Palese, Peter, additional, García-Sastre, Adolfo, additional, Simon, Viviana, additional, and Krammer, Florian, additional

Published
2022
Full Text
View/download PDF

7. Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial

Author

Pitisuttithum, Punnee, primary, Luvira, Viravarn, additional, Lawpoolsri, Saranath, additional, Muangnoicharoen, Sant, additional, Kamolratanakul, Supitcha, additional, Sivakorn, Chaisith, additional, Narakorn, Piengthong, additional, Surichan, Somchaiya, additional, Prangpratanporn, Sumalee, additional, Puksuriwong, Suttida, additional, Lamola, Steven, additional, Mercer, Laina D, additional, Raghunandan, Rama, additional, Sun, Weina, additional, Liu, Yonghong, additional, Carreño, Juan Manuel, additional, Scharf, Rami, additional, Phumratanaprapin, Weerapong, additional, Amanat, Fatima, additional, Gagnon, Luc, additional, Hsieh, Ching-Lin, additional, Kaweepornpoj, Ruangchai, additional, Khan, Sarwat, additional, Lal, Manjari, additional, McCroskery, Stephen, additional, McLellan, Jason, additional, Mena, Ignacio, additional, Meseck, Marcia, additional, Phonrat, Benjaluck, additional, Sabmee, Yupa, additional, Singchareon, Ratsamikorn, additional, Slamanig, Stefan, additional, Suthepakul, Nava, additional, Tcheou, Johnstone, additional, Thantamnu, Narumon, additional, Theerasurakarn, Sompone, additional, Tran, Steven, additional, Vilasmongkolchai, Thanakrit, additional, White, Jessica A, additional, Garcia-Sastre, Adolfo, additional, Palese, Peter, additional, Krammer, Florian, additional, Poopipatpol, Kittisak, additional, Wirachwong, Ponthip, additional, Hjorth, Richard, additional, and Innis, Bruce L, additional

Published
2021
Full Text
View/download PDF

8. A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters

Author

Sun, Weina, primary, Liu, Yonghong, additional, Amanat, Fatima, additional, González-Domínguez, Irene, additional, McCroskery, Stephen, additional, Slamanig, Stefan, additional, Coughlan, Lynda, additional, Rosado, Victoria, additional, Lemus, Nicholas, additional, Jangra, Sonia, additional, Rathnasinghe, Raveen, additional, Schotsaert, Michael, additional, Martinez, Jose, additional, Sano, Kaori, additional, Mena, Ignacio, additional, Innis, Bruce L, additional, Wirachwong, Ponthip, additional, Thai, Duong Huu, additional, Oliveira, Ricardo Das Neves, additional, Scharf, Rami, additional, Hjorth, Richard, additional, Raghunandan, Rama, additional, Krammer, Florian, additional, García-Sastre, Adolfo, additional, and Palese, Peter, additional

Published
2021
Full Text
View/download PDF

11. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: Addressing the threat of an influenza pandemic

Author

Surichan, Somchaiya, primary, Wirachwong, Ponthip, additional, Supachaturas, Wutichai, additional, Utid, Kanchala, additional, Theerasurakarn, Sompone, additional, Langsanam, Pimsuk, additional, Lakornrach, Pattharachai, additional, Nitisaporn, Ladda, additional, Chansikkakorn, Chanpen, additional, Vangkanonta, Wilak, additional, Kaweepornpoj, Ruangchai, additional, Poopipatpol, Kittisak, additional, Thirapakpoomanunt, Sit, additional, Srichainak, Somchai, additional, Artavatkun, Witit, additional, Chokevivat, Vichai, additional, and Wibulpolprasert, Suwit, additional

Published
2011
Full Text
View/download PDF

13. Downregulation of p-ERK1/2 and p-AKT expression by curcumin and tetrahydrocurcumin in hepatocellular carcinoma-induced tumors in nude mice

Author

Chintana, Pornphrom Yoysungnoen, Wirachwong, Ponthip, Suksamrarn, Apichart, and Patumraj, Suthiluk

Abstract

Background: Curcumin (CUR) and tetrahydrocurcumin (THC) inhibits tumor angiogenesis. It is suggested that tumor progress may be related to the pathway of extracellular signal-regulated kinase 1/2 (ERK1/2) and serine/threonine kinase AKT, but the mechanism remains unclear.

Published
2011
Full Text
View/download PDF

14. Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.

Author

Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C, Narakorn P, Surichan S, Prangpratanporn S, Puksuriwong S, Lamola S, Mercer LD, Raghunandan R, Sun W, Liu Y, Carreño JM, Scharf R, Phumratanaprapin W, Amanat F, Gagnon L, Hsieh CL, Kaweepornpoj R, Khan S, Lal M, McCroskery S, McLellan J, Mena I, Meseck M, Phonrat B, Sabmee Y, Singchareon R, Slamanig S, Suthepakul N, Tcheou J, Thantamnu N, Theerasurakarn S, Tran S, Vilasmongkolchai T, White JA, Garcia-Sastre A, Palese P, Krammer F, Poopipatpol K, Wirachwong P, Hjorth R, and Innis BL

Abstract

Background: Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It's being developed in Thailand, Vietnam, and Brazil; herein are initial results from Thailand., Methods: This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy adults aged 18-59 years, non-pregnant and negative for SARS-CoV-2 antibodies were eligible. Participants were block randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1 µg±CpG1018 (a toll-like receptor 9 agonist), 3 µg±CpG1018, 10 µg, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively. Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation). An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity through day 43 per protocol. ClinicalTrials.gov ( NCT04764422 )., Findings: Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enrolled (35 per group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees, all predominantly mild, were injection site pain (<63%), fatigue (<35%), headache (<32%), and myalgia (<32%). The proportion reporting a vaccine-related AE ranged from 5·7% to 17·1% among vaccine groups and was 2·9% in controls; there was no vaccine-related serious adverse event. The 10 µg formulation's immunogenicity ranked best, followed by 3 µg+CpG1018, 3 µg, 1 µg+CpG1018, and 1 µg formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from 122·23 IU/mL (1 µg, 95% CI 86·40-172·91) to 474·35 IU/mL (10 µg, 95% CI 320·90-701·19), with 93·9% to 100% of vaccine groups attaining a ≥4-fold increase over baseline., Interpretation: NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 µg and 3 µg+CpG1018 formulations advanced to phase 2., Funding: National Vaccine Institute (Thailand), National Research Council (Thailand), Bill & Melinda Gates Foundation, National Institutes of Health (USA).

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results